ERCC4 and lung cancer: In addition to these studies, we previously performed a high-throughput screen using the NCI-DTP (National Cancer Institute Developmental Therapeutics Program) diversity set and identified the compounds NSC16168 (Figure 1A) and NSC143099, which were potent and selective inhibitors of ERCC1/XPF activity both in biochemical assays as well as in lung cancer cell lines [14].